XML 39 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Marketable Securities and Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial assets and liabilities measured at fair value on a recurring basis
The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2014:
 
 
Fair Value Measurements at
 
September 30, 2014
 
Total
 
Using Quoted Prices
in Active Markets
for Identical Assets
(Level 1)
 
Using Significant
Other Unobservable
Inputs
(Level 2)
 
Using Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
67,174,763

 
$
67,174,763

 
$

 
$

Mutual funds
29,457,773

 

 
29,457,773

 

Municipal bonds
801,512

 

 
801,512

 

Investment in affiliated entity
8,998,375

 
8,998,375

 

 

Common stock warrants
591,000

 

 

 
591,000

Total Assets
$
107,023,423

 
$
76,173,138

 
$
30,259,285

 
$
591,000

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
2,207,388

 
$

 
$

 
$
2,207,388

Total Liabilities
$
2,207,388

 
$

 
$

 
$
2,207,388


The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2013:
 
 
Fair Value Measurements at
 
December 31, 2013
 
Total
 
Using Quoted Prices
in Active Markets
for Identical Assets
(Level 1)
 
Using Significant
Other Unobservable
Inputs
(Level 2)
 
Using Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Money market funds
$
26,852,560

 
$
26,852,560

 
$

 
$

Mutual funds
18,099,904

 

 
18,099,904

 

Municipal bonds
805,704

 

 
805,704

 

Investment in affiliated entity
9,664,587

 
9,664,587

 

 

Common stock warrants
717,500

 

 

 
717,500

Total Assets
$
56,140,255

 
$
36,517,147

 
$
18,905,608

 
$
717,500

Liabilities:
 
 
 
 
 
 
 
Common stock warrants
$
19,540,583

 
$

 
$

 
$
19,540,583

Total Liabilities
$
19,540,583

 
$

 
$

 
$
19,540,583

Assumptions used to estimate the fair values of the common stock warrants
September 30, 2014 are presented below:
 
Risk-free interest rate
1.43%
Expected volatility
78%
Expected life in years
4
Dividend yield
Change in fair value of the financial assets
The following table presents a summary of changes in fair value of the Company’s total Level 3 financial assets for the nine months ended September 30, 2014:
Balance at January 1, 2014
$
717,500

Decrease in fair value included in change in fair value of common stock warrants
(126,500
)
Balance at September 30, 2014
$
591,000


Changes in fair value of the financial liabilities
The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the nine months ended September 30, 2014:
 
Balance at January 1, 2014
$
19,540,583

Decrease in fair value included in change in fair value of common stock warrants
(330,984
)
Change in classification from liability to stockholders' equity due to warrant exercise
(17,002,211
)
Balance at September 30, 2014
$
2,207,388

OncoSec [Member]
 
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Assumptions used to estimate the fair values of the common stock warrants
The assumptions used to estimate the fair values of the OncoSec common stock warrants at September 30, 2014 are presented below:

Risk-free interest rate
0.58-0.83%
Expected volatility
85%
Expected life in years
2.00-2.50
Dividend yield